Skip to content

This Speculative Biotech’s Treatment Candidate For Head And Neck Cancer Gives It Massive Upside Potential

With the global market for head and neck cancer expected to reach $4.5 billion by 2027, the clinical-stage immuno-oncology company highlighted in today’s article – which has entered into a clinical trial collaboration with Merck to treat patients with head and neck squamous cell carcinoma with its lead product candidate – has massive upside potential. For more on this company and why the author believes it’s a good speculative biotech to buy, CLICK HERE.